26264-28-8 Usage
Uses
Used in Pharmaceutical Industry:
Cyanocobalamin-e-monocarboxylic acid is used as an impurity in the commercial preparation of Cyanocobalamin for the production of Vitamin B12 supplements. This is because it is a naturally occurring impurity in the synthesis process of Cyanocobalamin, which is essential for the normal functioning of the brain and nervous system, and for the formation of blood.
Used in Nutritional Supplements:
Cyanocobalamin-e-monocarboxylic acid is used as a component in Vitamin B12 supplements, which are essential for maintaining healthy brain and nervous system function, as well as for the production of red blood cells. The presence of this impurity in the commercial preparation of Cyanocobalamin ensures that consumers receive the necessary benefits of Vitamin B12 for their overall health and well-being.
Check Digit Verification of cas no
The CAS Registry Mumber 26264-28-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,6,2,6 and 4 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 26264-28:
(7*2)+(6*6)+(5*2)+(4*6)+(3*4)+(2*2)+(1*8)=108
108 % 10 = 8
So 26264-28-8 is a valid CAS Registry Number.
26264-28-8Relevant academic research and scientific papers
COBALAMINE DERIVATIVES USEFUL FOR DIAGNOSIS AND TREATMENT OF ABNORMAL CELLULAR PROLIFERATION
-
Page/Page column 18-19, (2008/06/13)
The invention relates to cobalamin derivatives (a) having no binding affinity or low binding affinity to the transport protein transcobalamin II TCII) and (b) retaining activity as a vitamin B12 substitute, optionally carrying a therapeutic and/or diagnostic agent, such as a radioactive metal. These compounds have a much reduced accumulation rate in blood and benign organs, such as kidney and liver, compared to the accumulation rate in neoplastic tissues, and are more rapidly eliminated from blood. The invention further relates to a method of diagnosis and a method of treatment of a neoplastic disease or an infection by microorganisms in a mammal comprising (a) exposing the mammal to a period of a vitamin B12 - free diet, and (b) subsequently applying a cobalamin derivative of the invention carrying a diagnostic and/or therapeutic agent. By selecting cobalamin derivatives acting as vitamin B12 substitutes, the risk of the formation of resistant off-spring in neoplastic tissue is much reduced.
